Kyowa Kirin Appoints Julie Dehaene-Puype As President For International Region; Strengthens Global Leadership

Kyowa Kirin International (KKI), part of Kyowa Kirin Co., Ltd., a Japan-based global specialty pharmaceutical company, has announced the appointment of Julie Dehaene-Puype as President for the International Region, effective November 1, 2025. She succeeds Jeremy Morgan, who has led the region since 2023 and will continue to serve as an advisor through the end of 2025, ensuring a seamless transition of leadership.

“We are very pleased to welcome Julie to the company in the role as President of KKI,” said Tomohiro Sudo, Chief International Business Officer of Kyowa Kirin. “Julie joins us with extensive experience in global biotech and pharma spanning a 25-year career. I am confident that her expertise and her strong passion and care for people and patients will significantly contribute to KKI’s future growth for patients’ smiles, and we are looking forward to working in partnership with her toward our Vision for 2030.”

Julie Dehaene-Puype brings over 25 years of global pharmaceutical experience, spanning general management, commercial strategy, new product development, and regulatory affairs. Her career includes leadership roles at Mundipharma, Takeda, Merck/MSD, and Schering-Plough, and she currently serves as a Non-Executive Director on the board of Lytix Biopharma. Julie holds a PharmD, a Master’s in Pharmaceutical Regulatory Affairs, and a Master’s in Biological and Medical Sciences from the University of Lille, France. Based in Switzerland, she will maintain close engagement with the Marlow, UK headquarters and country offices across the region.

“I want to thank Jeremy Morgan on behalf of Kyowa Kirin,” said Abdul Mullick, Ph.D., President and COO of Kyowa Kirin. “For his unwavering leadership and care for KKI employees, and for putting patients first. From the moment Jeremy joined KKI, he brought a purpose and an energy for the needs of the communities we serve. We thank Jeremy for the lasting impact he has made whilst at the helm of Kyowa Kirin, and for carrying the business through transformation into a stable, growing organization that is truly living our purpose to make people smile.”

The appointment aligns with Kyowa Kirin’s broader organizational evolution, following the introduction of a dual CEO-COO leadership structure earlier in 2025. Under this model, Abdul Mullick was appointed President and COO, responsible for driving the execution of global operations to support the company’s continued growth and strategic expansion.

“I am thrilled to be joining Kyowa Kirin - a company with a 76-year legacy of science, innovation and partnership, and a deep commitment to advancing care in rare diseases and oncology,” stated Dehaene-Puype. “From my first days, I can already feel the passion and drive of the people at KKI, united by a shared purpose: To make more people smile. I look forward to working with my new colleagues to deliver even more for the patients who place their trust in us.”